Raskind Murray A, Thompson Charles, Petrie Eric C, Dobie Dorcas J, Rein Rebekah J, Hoff David J, McFall Miles E, Peskind Elaine R
Northwest Network Mental Illness Research, Education and Clinical Center, VA Puget Sound Health Care System and University of Washington, Seattle 98108, USA.
J Clin Psychiatry. 2002 Jul;63(7):565-8. doi: 10.4088/jcp.v63n0705.
Preclinical and clinical observations suggest that the centrally active alpha1-adrenergic antagonist prazosin might alleviate trauma content nightmares and other symptoms in combat veterans with chronic posttraumatic stress disorder (PTSD).
In this retrospective chart review study, we analyzed data from 59 consecutive combat veterans with previously treatment-resistant chronic PTSD (DSM-IV criteria) and severe intractable trauma content nightmares to whom prazosin had been prescribed. Nightmare severity was quantified using the recurrent distressing dreams item of the Clinician Administered PTSD Scale (CAPS). Change in overall PTSD severity exclusive of nightmares was estimated by assigning a Clinical Global Impressions-Change scale (CGI-C) score based on chart review.
Mean +/- SEM recurrent distressing dreams item scores improved significantly (7.0 +/- 0.2 to 3.5 +/- 0.3, p <.0001) in the 36 patients who completed at least 8 weeks of prazosin treatment at their maximum titrated dose. The mean maximum prazosin dose achieved in these 36 patients was 9.6 +/- 0.9 mg/day. Recurrent distressing dreams scores also improved in the total group who filled their prazosin prescriptions (N = 51) (7.1 +/- 0.2 to 4.2 +/- 0.3, p <.0001). In a comparison group of 8 patients who did not fill their prazosin prescriptions but continued in outpatient treatment, there was no significant change in CAPS recurrent distressing dreams score (6.8 +/- 0.5 to 6.7 +/- 0.4). There also was at least some improvement in CGI-C ratings of overall PTSD severity exclusive of nightmares in a substantial majority of patients receiving prazosin, but not in the 8 comparison subjects. There were no serious adverse effects attributable to prazosin.
These observations suggest that prazosin may relieve symptomatic distress in PTSD, and they provide rationale for placebo-controlled trials of prazosin for PTSD trauma content nightmares and other PTSD symptoms.
临床前和临床观察表明,具有中枢活性的α1肾上腺素能拮抗剂哌唑嗪可能会缓解患有慢性创伤后应激障碍(PTSD)的退伍军人的创伤相关噩梦及其他症状。
在这项回顾性病历审查研究中,我们分析了59例连续的患有先前治疗抵抗性慢性PTSD(DSM-IV标准)且有严重顽固性创伤相关噩梦的退伍军人的数据,这些患者均已开具哌唑嗪处方。使用临床医生管理的PTSD量表(CAPS)中的反复痛苦梦境项目对噩梦严重程度进行量化。通过基于病历审查分配临床总体印象变化量表(CGI-C)评分来估计不包括噩梦的总体PTSD严重程度的变化。
在36例以最大滴定剂量完成至少8周哌唑嗪治疗的患者中,平均±标准误反复痛苦梦境项目评分显著改善(从7.0±0.2降至3.5±0.3,p<.0001)。这36例患者达到的平均最大哌唑嗪剂量为9.6±0.9毫克/天。在填写哌唑嗪处方的全部患者组(N = 51)中,反复痛苦梦境评分也有所改善(从7.1±0.2降至4.2±0.3,p<.0001)。在8例未填写哌唑嗪处方但继续接受门诊治疗的患者组成的对照组中,CAPS反复痛苦梦境评分无显著变化(从6.8±0.5降至6.7±0.4)。在接受哌唑嗪治疗的绝大多数患者中,不包括噩梦的总体PTSD严重程度的CGI-C评分也至少有一些改善,但8例对照受试者中未出现这种情况。没有可归因于哌唑嗪的严重不良反应。
这些观察结果表明,哌唑嗪可能缓解PTSD中的症状性困扰,并为哌唑嗪治疗PTSD创伤相关噩梦及其他PTSD症状的安慰剂对照试验提供了理论依据。